UA93814U - A method for diagnosing syndrome of retardation of fetus development and the degree of its severity - Google Patents
A method for diagnosing syndrome of retardation of fetus development and the degree of its severityInfo
- Publication number
- UA93814U UA93814U UAU201406263U UAU201406263U UA93814U UA 93814 U UA93814 U UA 93814U UA U201406263 U UAU201406263 U UA U201406263U UA U201406263 U UAU201406263 U UA U201406263U UA 93814 U UA93814 U UA 93814U
- Authority
- UA
- Ukraine
- Prior art keywords
- concentration
- weeks
- degree
- vegf
- retardation
- Prior art date
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The method for diagnosing fetal growth retardation and determination of the degree of its severity includes determination in woman's blood of placental dysfunction markers. Determined is the dynamics of changes in concentration of receptor of vascular endothelial growth factor (VEGF-R1) at different stages of pregnancy. At concentration of VEGF-R1 (2,32 ± 0,10) ng / ml at 16-19 weeks, at concentration (2,45 ± 0,18) ng / ml at 20-27 weeks, at concentration of (2,8 ± 0.21) ng / ml at 28-32 weeks, at concentration (4,25 ± 0,16) ng / ml at 33-37 weeks and at concentration (3,92 ± 0,12) ng / ml at 38- 40 weeks with the syndrome of fetal growth retardation (SFGR) of I degree is diagnosed. At concentration of VEGF-R1 (2,88 ± 0,77) ng / ml at 16-19 weeks, at concentration (3,84 ± 0,54) ng / ml at 20-27 weeks, at concentration (8,22 ± 0.66) ng / ml at 28-32 weeks, at concentration (9,86 ± 0,72) ng / ml at 33-37 weeks and at concentration (9,16 ± 0,54) ng / ml at 38- 40 weeks SFGR of II degree is diagnosed. At concentration of VEGF-R1 (4,24 ± 0,62) ng / ml at 16-19 weeks, at concentration (9,92 ± 0,88) ng / mlat 20-27 weeks with concentration of (11,4 ± 0.79) ng / ml at 28-32 weeks and at concentration (10,2 ± 0,76) ng / ml at 33-37 weeks SFGR of III degree is diagnosed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAU201406263U UA93814U (en) | 2014-06-06 | 2014-06-06 | A method for diagnosing syndrome of retardation of fetus development and the degree of its severity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAU201406263U UA93814U (en) | 2014-06-06 | 2014-06-06 | A method for diagnosing syndrome of retardation of fetus development and the degree of its severity |
Publications (1)
Publication Number | Publication Date |
---|---|
UA93814U true UA93814U (en) | 2014-10-10 |
Family
ID=56277739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAU201406263U UA93814U (en) | 2014-06-06 | 2014-06-06 | A method for diagnosing syndrome of retardation of fetus development and the degree of its severity |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA93814U (en) |
-
2014
- 2014-06-06 UA UAU201406263U patent/UA93814U/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018208091A3 (en) | Biomarker for monitoring or diagnosing onset of liver cancer in high-risk group for liver cancer and use thereof | |
WO2015157704A3 (en) | Methods and compositions for detecting misfolded proteins | |
WO2014099919A3 (en) | Noninvasive detection of fetal aneuploidy in egg donor pregnancies | |
EP3495502A3 (en) | Biomarkers for premature birth | |
EP3637105A3 (en) | Methods for predicting time-to-delivery in pregnant women | |
EP3492607A3 (en) | Urinary mirnas for the in vitro diagnosis of bladder cancer | |
UA93814U (en) | A method for diagnosing syndrome of retardation of fetus development and the degree of its severity | |
WO2015173430A3 (en) | Early placenta insulin-like peptide (pro-epil) | |
RU2013125276A (en) | METHOD FOR PREDICTING PREECLAMPSIA IN PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY | |
RU2010148706A (en) | METHOD FOR DETERMINING HISTAMINE INCREASE IN PREGNANT BLOOD UNDER INFLUENCE OF ARGININDEHYDROGENASE ACTIVITY GROWTH IN PLACENTA SINCITIOTROFOBLAST CAUSED BY TREASIS AGAINST THREE AREA. | |
WO2015155523A3 (en) | Carrier status of annexin a5 m2 haplotype and obstetric risks | |
EP2846285A3 (en) | Risk stratification of suspected AMI patients | |
UA131761U (en) | METHOD OF PRECLINICAL DIAGNOSIS OF PLACENTAL INSUFFICIENCY IN PREGNANT WOMEN ON THE BACKGROUND OF GESTATIONAL ENDOTHELIOPATHY | |
UA95701U (en) | Method for diagnosing endothelial dysfunction in adolescents with arterial hypertension and hyperuricemia | |
UA96344U (en) | METHOD OF DIAGNOSIS OF FRUIT Growth Delay Syndrome in Pregnant Women with Placental Dysfunction | |
UA91252U (en) | Method for predicting intrauterine infection of fetus in incomplete pregnancy and premature rupture of fetal membranes | |
UA125540U (en) | METHOD OF PREVENTION OF DEVELOPMENT OF PLACENTAR DYSFUNCTION IN HIV-INFECTED PREGNANCY | |
UA78016U (en) | method for diagnosis of intrauterine fetal placental dysfunction in the III trimester of pregnancy | |
RU2014146126A (en) | METHOD FOR IDENTIFYING RISK GROUPS OF ARTERIAL HYPERTENSION IN WOMEN WITH OBESITY DURING PREGNANCY | |
UA106446U (en) | A method for diagnosing endothelial dysfunction and its correction in patients with acute epididymitis | |
郭祯 | Evaluations on TEM-4 Oral Test | |
Khan et al. | A COMPARISON OF AMERICAN THYROID ASSOCIATION AND CONVENTIONAL CRITERIA: IN EVALUATION OF THYROID HORMONE PROFILE OF CLINICALLY EUTHYROID PREGNANT WOMEN ATTENDING IN A TERTIARY HOSPITAL OF BANGLADESH | |
Lagarce | Medical termination of pregnancy following premature rupture of membranes and oligohydramnios in mother and arthrogryposis in fetus: 2 case reports | |
杨静 | Selection and evaluation of clinical diagnostic cut point of glycated albumin | |
UA94059U (en) | Method for diagnosing fracture healing |